Question · Q3 2023
Asked for the reasons behind vein-to-vein times exceeding the 7-day target and inquired about any ongoing efforts to optimize this timeline.
Answer
The 7-day vein-to-vein time is achieved consistently. The few exceptions where the time was slightly longer (8-9 days) were due to patient-related factors like low cell yield or a single instance of a manufacturing restart. It was stressed that all patients were treated within 14 days, which is highly competitive, and that good efficacy was still observed in these cases.